Hero

Celyad Announces Third Quarter 2017 Business Update

1

Celyad Announces Third Quarter 2017 Business Update

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

2

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad announces new agreements with Celdara Medical and Dartmouth College

3

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

4

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

5

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Letter to Shareholders - December 2017

Letter to Shareholders - December 2017

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Discover all news

Carousel

Social Feed

Great interview about ambitions for universal CAR-T w/ our CEO Christian Homsy $CYAD at this year's Biotech Showcas… https://t.co/x3jKVXFJJH

8 hours ago

Great interview about ambitions for universal CAR-T w/ our CEO Christian Homsy $CYAD at this year's Biotech Showcas… https://t.co/x3jKVXFJJH

RT @ChristianHomsy: Happy to present next Wednesday at the Precision Medicine World Conference Silicon Valley. Proud of @CelyadSA CAR T pa…

4 days ago

RT @ChristianHomsy: Happy to present next Wednesday at the Precision Medicine World Conference Silicon Valley. Proud of @CelyadSA CAR T pa…

RT @AmericanBanking: Zacks: Celyad SA $CYAD Given $74.00 Consensus Price Target by Analysts https://t.co/gBjeopKsi2 #stocks

1 week ago

RT @AmericanBanking: Zacks: Celyad SA $CYAD Given $74.00 Consensus Price Target by Analysts https://t.co/gBjeopKsi2 #stocks

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.

2 weeks ago

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.

Great interview about ambitions for universal CAR-T w/ our CEO Christian Homsy $CYAD at this year's Biotech Showcas… https://t.co/x3jKVXFJJH

8 hours ago

Great interview about ambitions for universal CAR-T w/ our CEO Christian Homsy $CYAD at this year's Biotech Showcas… https://t.co/x3jKVXFJJH

RT @ChristianHomsy: Happy to present next Wednesday at the Precision Medicine World Conference Silicon Valley. Proud of @CelyadSA CAR T pa…

4 days ago

RT @ChristianHomsy: Happy to present next Wednesday at the Precision Medicine World Conference Silicon Valley. Proud of @CelyadSA CAR T pa…

RT @AmericanBanking: Zacks: Celyad SA $CYAD Given $74.00 Consensus Price Target by Analysts https://t.co/gBjeopKsi2 #stocks

1 week ago

RT @AmericanBanking: Zacks: Celyad SA $CYAD Given $74.00 Consensus Price Target by Analysts https://t.co/gBjeopKsi2 #stocks

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.

2 weeks ago

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.